Table 1.
Serovars | SGI1-positive n (%) | SGI1-negative n (%) |
---|---|---|
S. Typhimurium (n = 36) | 7 (19.4) | 29 (80.6) |
DT104 (n = 9) | 5 (55.6) | 4 (44.4) |
Non DT104 (n = 27) | 2 (7.4) | 25 (92.6) |
Non S. Typhimurium serovars (n = 64) | 5 (7.8) | 59 (92.2) |
S. 4, [5], 12: i- (n = 19) | 0 | 19 (100) |
S. Enteritidis (n = 14) | 0 | 14 (100) |
S. Paratyphi B var. Java (n = 2) | 0 | 2 (100) |
S. Dublin (n = 5) | 0 | 5 (100) |
Other serovarsa (n = 24) | 5b (20.8) | 19 (79.2) |
Phenotypesc | SGI1-positive n (%) | SGI1-negative n (%) |
Pansusceptible (n = 21) | 0 (0) | 21 (100) |
Resistant ≥1 (n = 79) | 12 (15.2) | 67 (84.8) |
Including penta-resistant (ACSSuT)d (n = 9) | 6 (67) | 3 (33) |
aOther serovars (n = 24): S. Ahmadi (n = 1). S. Braenderup (n = 1). S. Chester (n = 2). S. Eastbourne (n = 1). S. Eboko (n = 1). S. Hadar (n = 1). S. Hessarek (n = 2); S. Infantis (n = 2); S. Kedougou (n = 1); S. Kentucky (n = 2); S. Napoli (n = 1); S. Panama (n = 1); S. Rissen (n = 1); S. Schwarzengrund (n = 2); S. Singapore (n = 1); S. St Paul (n = 3); and a new variant: 6, 7, − (n = 1)
bOther serovars with SGI1 (n = 5): S. Infantis (n = 1), S. Kentucky (n = 2), S. St Paul (n = 2)
cPhenotype was determined by testing amoxicillin, amoxicillin – clavulanic acid, ceftriaxone, nalidixic acid, chloramphenicol, kanamycin, spectinomycin, streptomycin, sulphonamides, trimethoprim and doxycycline in accordance to the antibiomicrobial guidelines of CASFM- EUCAST
dACSSuT: Amoxicillin, Chloramphenicol, Streptomycin, Sulphonamides and Tetracyclines